Next-generation drug testing on chips
Researchers in Japan have designed a small 'body-on-a-chip' device that can test the side effects of drugs on human cells...
List view / Grid view
Researchers in Japan have designed a small 'body-on-a-chip' device that can test the side effects of drugs on human cells...
A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK...
Researchers have developed a method that could make magnetic resonance imaging (MRI) multicoloured - a strategy that could serve as a research tool and even aid disease diagnosis...
NICE has recommended sorafenib to be routinely available for patients on the NHS making it one of the 24 drugs appraised from the CDF...
Researchers have identified a drug regimen administered prior to and after surgery that significantly reduces the risk of post-surgical cancer recurrence...
Researchers have discovered properties of the precious metal that allow catalytic abilities to be accessed in living things without any side effects...
Engineers have devised a non-invasive way to assess a cell's mechanical properties simply by observation...
After the first half of 2017 biopharma investors are in a position to be exuberant, the threat of US price controls that have overshadowed the sector for a year have largely disappeared...
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
The UK's proposed withdrawal from Euratom may threaten the supply of essential medical isotopes, putting cancer patients at risk...
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
Perhaps the most significant challenge in all of medicine is the need for more effective treatments for cancer, which causes one of every four deaths in the United States and bears a direct cost to our healthcare system of close to $100bn annually.
2 June 2017 | By Niamh Marriott, Junior Editor
ESMO welcomes the adoption of cancer resolution on prevention and control in the context of an integrated approach during the 70th World Health Assembly...
19 May 2017 | By Sarah Wills, Editorial Assistant: European Pharmaceutical Review
While there have been improvements in some areas of cancer prevention and early detection, the use of potentially lifesaving measures is suboptimal and strongly influenced by individual behaviours, as well as social, economic, and public policy factors, according to a new report from the American Cancer Society.
15 March 2017 | By Steve Bremer, Managing Editor
Tumour therapy, particularly in the case of multidrug resistant cancers, could be significantly enhanced by using siRNA to down-regulate the production...